Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 19.8%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 3,000,764 shares, a growth of 19.8% from the March 31st total of 2,504,815 shares. Based on an average daily volume of 431,609 shares, the days-to-cover ratio is currently 7.0 days. Approximately 7.9% of the shares of the company are sold short.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of institutional investors have recently modified their holdings of the company. State of Wyoming purchased a new stake in SAB Biotherapeutics in the 4th quarter valued at $34,000. State Street Corp bought a new position in SAB Biotherapeutics in the 4th quarter valued at $49,000. Fifth Lane Capital LP bought a new position in SAB Biotherapeutics in the 4th quarter valued at $56,000. ADAR1 Capital Management LLC bought a new position in SAB Biotherapeutics in the 3rd quarter valued at $30,000. Finally, Dimensional Fund Advisors LP bought a new position in SAB Biotherapeutics in the 3rd quarter valued at $32,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Trading Down 7.2%

Shares of SAB Biotherapeutics stock traded down $0.27 on Friday, reaching $3.47. 627,365 shares of the company’s stock were exchanged, compared to its average volume of 532,147. The company has a market capitalization of $176.80 million, a P/E ratio of -1.50 and a beta of 0.60. SAB Biotherapeutics has a 52 week low of $1.53 and a 52 week high of $6.60. The firm’s 50-day moving average is $3.87 and its two-hundred day moving average is $3.74. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.46 and a current ratio of 9.46.

SAB Biotherapeutics (NASDAQ:SABS) last issued its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). Sell-side analysts predict that SAB Biotherapeutics will post -0.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Rodman & Renshaw assumed coverage on SAB Biotherapeutics in a research report on Thursday, April 2nd. They set a “buy” rating and a $13.00 price objective on the stock. HC Wainwright decreased their target price on SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, March 10th. Zacks Research cut shares of SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, March 12th. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. Finally, Wall Street Zen cut shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.50.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.